Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease

安慰剂 痴呆 临床终点 阿尔茨海默病 疾病 临床痴呆评级 临床试验 内科学 生物标志物 随机对照试验 认知 肿瘤科 医学 病理 精神科 替代医学 化学 生物化学
作者
Samantha Budd Haeberlein,Paul Aisen,Frederik Barkhof,Spyros Chalkias,Tianle Chen,Sarah Cohen,Gersham Dent,Oskar Hansson,Katie Harrison,Christian von Hehn,Takeshi Iwatsubo,Craig Mallinckrodt,Cath Mummery,Kumar Kandadi Muralidharan,Ivan Nestorov,Laura Nisenbaum,Raj Rajagovindan,LeAnne Skordos,Y. Tian,Christopher H. van Dyck
出处
期刊:JPAD [Springer Science+Business Media]
卷期号:9 (2): 197-210 被引量:1284
标识
DOI:10.14283/jpad.2022.30
摘要

BACKGROUND: Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. OBJECTIVES: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease. DESIGN: EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease. SETTING: These studies involved 348 sites in 20 countries. PARTICIPANTS: Participants included 1638 (EMERGE) and 1647 (ENGAGE) patients (aged 50-85 years, confirmed amyloid pathology) who met clinical criteria for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia, of which 1812 (55.2%) completed the study. INTERVENTION: Participants were randomly assigned 1:1:1 to receive aducanumab low dose (3 or 6 mg/kg target dose), high dose (10 mg/kg target dose), or placebo via IV infusion once every 4 weeks over 76 weeks. MEASUREMENTS: The primary outcome measure was change from baseline to week 78 on the Clinical Dementia Rating Sum of Boxes (CDR-SB), an integrated scale that assesses both function and cognition. Other measures included safety assessments; secondary and tertiary clinical outcomes that assessed cognition, function, and behavior; and biomarker endpoints. RESULTS: EMERGE and ENGAGE were halted based on futility analysis of data pooled from the first approximately 50% of enrolled patients; subsequent efficacy analyses included data from a larger data set collected up to futility declaration and followed prespecified statistical analyses. The primary endpoint was met in EMERGE (difference of -0.39 for high-dose aducanumab vs placebo [95% CI, -0.69 to -0.09; P=.012; 22% decrease]) but not in ENGAGE (difference of 0.03, [95% CI, -0.26 to 0.33; P=.833; 2% increase]). Results of biomarker substudies confirmed target engagement and dose-dependent reduction in markers of Alzheimer's disease pathophysiology. The most common adverse event was amyloid-related imaging abnormalities-edema. CONCLUSIONS: Data from EMERGE demonstrated a statistically significant change across all four primary and secondary clinical endpoints. ENGAGE did not meet its primary or secondary endpoints. A dose- and time-dependent reduction in pathophysiological markers of Alzheimer's disease was observed in both trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
joleisalau完成签到,获得积分10
1秒前
成就的小丸子完成签到,获得积分20
1秒前
2秒前
2秒前
3秒前
韩晓蕊完成签到,获得积分10
3秒前
Dzzz完成签到,获得积分10
3秒前
shenkekeshen的应助被沉静的安青采纳,获得10
3秒前
4秒前
李美美完成签到 ,获得积分10
4秒前
Kyrie完成签到,获得积分10
4秒前
6秒前
7秒前
JamesPei的应助被开朗的曼柔采纳,获得10
8秒前
科研通AI6.4的应助被taoshiren采纳,获得10
8秒前
邱邱科研完成签到,获得积分10
9秒前
爆米花的应助被苒苒采纳,获得30
11秒前
科研通AI6.2的应助被Daria采纳,获得10
12秒前
星辰大海的应助被科研通管家采纳,获得10
13秒前
Crssss的应助被科研通管家采纳,获得30
13秒前
小蘑菇的应助被科研通管家采纳,获得10
13秒前
烟花的应助被科研通管家采纳,获得10
13秒前
CarryLJR的应助被科研通管家采纳,获得10
13秒前
13秒前
阿皓要发nature完成签到,获得积分10
13秒前
追风少年的应助被科研通管家采纳,获得30
13秒前
乐乐的应助被科研通管家采纳,获得10
13秒前
CarryLJR的应助被科研通管家采纳,获得10
14秒前
英俊的铭的应助被科研通管家采纳,获得10
14秒前
科研通AI2S的应助被科研通管家采纳,获得10
14秒前
CarryLJR的应助被科研通管家采纳,获得10
14秒前
传奇3的应助被科研通管家采纳,获得10
14秒前
CarryLJR的应助被科研通管家采纳,获得10
14秒前
CarryLJR的应助被科研通管家采纳,获得10
14秒前
Maestro_S的应助被科研通管家采纳,获得10
15秒前
丘比特的应助被科研通管家采纳,获得10
15秒前
隐形曼青的应助被科研通管家采纳,获得10
15秒前
秋风的应助被科研通管家采纳,获得20
15秒前
深情安青的应助被科研通管家采纳,获得30
15秒前
orixero的应助被科研通管家采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189302
求助须知:如何正确求助?哪些是违规求助? 9576666
关于积分的说明 21849295
捐赠科研通 7787245
什么是DOI,文献DOI怎么找? 3435521
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509